Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 81-90 of 151 for Amyloidosis

Edit search filters
  1. A Study To Evaluate Pembrolizumab, Ixazomib Citrate, And Dexamethasone To Treat Participants With Relapsed Multiple Myeloma

    Rochester, MN

  2. First In Human (FIH) Study Of REGN5459 In Patients With Relapsed Or Refractory Multiple Myeloma (MM)

    Rochester, MN

  3. Idasanutlin, Ixazomib Citrate, And Dexamethasone In Treating Patients With Relapsed Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  4. Venetoclax, Ixazomib Citrate, And Dexamethasone In Treating Patients With Relapsed Multiple Myeloma

    Rochester, MN

  5. Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

    Rochester, MN

  6. Safety And Efficacy Of ALLO-715 And ALLO-647 BCMA Allogenic CAR T Cells In In Adults With Relapsed Or Refractory Multiple Myeloma (UNIVERSAL)

    Rochester, MN

  7. A Study In Subjects With Relapsed And Refractory Multiple Myeloma Receiving Carfilzomib In Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)

    Scottsdale/Phoenix, AZ

  8. Study Evaluating The Safety And Effectiveness Of JCARH125 In Subjects With Relapsed And/or Refractory Multiple Myeloma (EVOLVE)

    Rochester, MN

  9. Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. CC-220-MM-001: A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer